Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure

An Sinh Hospital71 enrolled

Overview

Atosiban, administered at embryo transfer, can improve the implantation rate and the clinical pregnancy rate in patients with repeated implantation failure undergoing IVF-ET (in-vitro fertilization and embryo transfer).

Atosiban is a mixed oxytocin and vasopressin V1A receptor antagonist.Combined antagonism at oxytocin and vasopressin V1A receptors reduces uterine contractions with a corresponding decrease in intrauterine production of prostaglandin F2alpha and improved uterine blood supply. These effects are of potential benefit for implantation support during IVF-ET cycles.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Repeated Implantation Failure

Interventions

atosibanDRUG

Atosiban was administered as a 6.75mg IV bolus dose 30 minutes prior to embryo transfer followed by a 1-hour IV infusion at dose of 18 mg/h then a 2-hour IV infusion at 6 mg/h.

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: * had repeated implantation failure * have at least 1 good quality embryo for transfer Exclusion Criteria: * uterine abnormalities that could compromise the implantation process (e.g. fibroids, endometrial polyp, bicornuate uterus, adhesion of uterine cavity)

Locations (1)

IVFAS, An Sinh Hospital

Ho Chi Minh City, Ho Chi Minh, Vietnam

Outcomes

Primary Outcomes

Clinical pregnancy

Time frame: 5 weeks after intervention

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.